FDA grants bedaquiline Priority Review for TB

FDA accepted and granted Priority Review to an NDA from Janssen Research & Development LLC for bedaquiline ( TMC207) to treat multi-drug resistant tuberculosis. The PDUFA date is Dec. 29. Bedaquiline is a diarylquinoline (DARQ) antibiotic that inhibits mycobacterial F1F0-ATP synthase. ...